Cugene Advances its Study of CUG252 to Phase1b, Recruiting Patients with Mild-to-Moderate SLE April 18, 2023
Cugene Presents Preclinical Data on TILKine-2 at the Society for Immunotherapy of Cancer (SITC 2021) Annual Meeting November 18, 2021
Cugene Receives FDA Approval for Phase 1a Healthy Volunteer Study of CUG252, a Treg-Selective Long-Acting IL-2 September 18, 2021
Cugene Presents Preclinical Data on CUG252 at the European E-Congress of Rheumatology (EULAR) 2020 June 18, 2020
